A Phase 2 interventional study of Enzalutamide in Metastatic Progressive Castration-resistant Prostate Cancer, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 57th largest by enrollment, is one of 3 that started in 2010, is one of 65 in phase 2, and was the 4th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 3 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is close to the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
42 studies in Prostatic Neoplasms by Pfizer: 3 open now, 8 under way, 5 of them phase 3. Of 33 finished, 28 (85%) have results posted.
Among the 42 studies in Prostatic Neoplasms by Pfizer, this one is the 24th largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2010, is one of 10 in phase 2, and was the 11th registered.
Pfizer’s Prostatic Neoplasms studies by the year they started, since 1998.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Pfizer’s 42 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to determine the effect of enzalutamide on the androgen signaling pathway in correlation with the anti-tumor effects of enzalutamide to identify potential predictors of response or resistance to therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression, unacceptable toxicity, or withdrawal.
Drug: Enzalutamide
Also known as: MDV3100
Change From Baseline in Bone Marrow Testosterone
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry.
Time frame: Baseline, Week 9
Change From Baseline in Bone Marrow Dihydrotestosterone
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry.
Time frame: Baseline, Week 9
Change From Baseline in Bone Marrow Testosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow testosterone levels at Week 9 was correlated with PSA response status at Week 9.
Time frame: Baseline, Week 9
Change From Baseline in Bone Marrow Dihydrotestosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow dihydrotestosterone levels at Week 9 was correlated with PSA response status at Week 9.
Time frame: Baseline, Week 9
Percentage of Participants at Week 9 With a Response in Prostate-Specific Antigen (PSA)
Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit.
Time frame: Baseline, Week 9
Median Time to Study Drug Discontinuation
Exposure to study drug through the data cutoff of 26AUG2011 only. Fifteen participants (25.0%) were still on study drug as of the data cut-off date and were censored at this date.
Time frame: Duration of study treatment through the data cutoff, up to 3 years.
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 5.
Time frame: Baseline, Week 5
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 9.
Time frame: Baseline, Week 9
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 17.
Time frame: Baseline, Week 17
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 25.
Time frame: Baseline, Week 25
Change From Baseline in Urinary N-Telopeptide
Time frame: Baseline, Week 33
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 41.
Time frame: Baseline, Week 41
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 49.
Time frame: Baseline, Week 49
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 57.
Time frame: Baseline, Week 57
Change From Baseline in Urinary N-Telopeptide
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 65.
Time frame: Baseline, Week 65
Single center clinical trial
| Milestone | Enzalutamide |
|---|---|
| Started | 60 |
| Completed | 56 |
| Not completed | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Progressive disease | 3 |
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry.
| ng/mL | Enzalutamide |
|---|---|
| Change From Baseline in Bone Marrow Testosterone | 0.05 ± 0.072 |
Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit.
| percentage of participants | Enzalutamide |
|---|---|
| >=50% Reduction in PSA from Baseline | 41.1 (28.1 to 55.0) |
| >=90% Reduction in PSA from Baseline | 21.4 (11.6 to 34.4) |
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry.
| ng/mL | Enzalutamide |
|---|---|
| Change From Baseline in Bone Marrow Dihydrotestosterone | 0.00 ± 0.022 |
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral testosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow testosterone levels at Week 9 was correlated with PSA response status at Week 9.
| ng/mL | Enzalutamide, PSA Responders at Week 9 | Enzalutamide, PSA Non-Responders at Week 9 |
|---|---|---|
| Change From Baseline in Bone Marrow Testosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status | 0.05 ± 0.107 | 0.05 ± 0.034 |
Bone marrow biopsies were performed at the Day 1 visit prior to initiation of enzalutamide administration. Repeat bone marrow biopsies were performed at the Week 9 visit. If a repeat bone marrow was not performed at the Week 9 visit or if a patient discontinued the study before the Week 9 visit, a bone marrow biopsy was obtained at the Safety Follow-up visit. Assessment of intratumoral dihydrotestosterone was assessed by liquid chromatography mass spectrometry. Serum samples for measurement of PSA levels were obtained at baseline prior to initiation of enzalutamide administration and at the Week 9 visit. The change from baseline in bone marrow dihydrotestosterone levels at Week 9 was correlated with PSA response status at Week 9.
| ng/mL | Enzalutamide, PSA Responders at Week 9 | Enzalutamide, PSA Non-Responders at Week 9 |
|---|---|---|
| Change From Baseline in Bone Marrow Dihydrotestosterone at Week 9 by Prostate-Specific Antigen (PSA) Response Status | -0.01 ± 0.034 | 0.00 ± 0.000 |
Exposure to study drug through the data cutoff of 26AUG2011 only. Fifteen participants (25.0%) were still on study drug as of the data cut-off date and were censored at this date.
| months | Enzalutamide |
|---|---|
| Median Time to Study Drug Discontinuation | 5.0 (3.6 to 6.0) |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 5.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | 34.81 ± 137.361 |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 9.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | 205.84 ± 1334.820 |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 17.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | -0.92 ± 205.941 |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 25.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | -18.96 ± 278.112 |
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | -89.36 ± 363.140 |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 41.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | -2.00 ± 22.414 |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 49.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | -2.36 ± 26.526 |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 57.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | -9.33 ± 37.824 |
Samples for measurement of urinary N-telopeptide were collected at baseline prior to initiation of enzalutamide administration and at Week 65.
| mmol/mmol creatinine | Enzalutamide |
|---|---|
| Change From Baseline in Urinary N-Telopeptide | 17.67 ± 17.131 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide | — | 13/60 (21.7%) | 59/60 (98.3%) |
| Event | Enzalutamide |
|---|---|
| Urinary tract infectionInfections and infestations | 2/60 |
| UrosepsisInfections and infestations | 2/60 |
| Angina pectorisCardiac disorders | 1/60 |
| Bundle branch block leftCardiac disorders | 1/60 |
| Myocardial infarctionCardiac disorders | 1/60 |
| Sinus bradycardiaCardiac disorders | 1/60 |
| Small intestinal obstructionGastrointestinal disorders | 1/60 |
| FatigueGeneral disorders | 1/60 |
| Periorbital cellulitisInfections and infestations | 1/60 |
| FallInjury, poisoning and procedural complications | 1/60 |
| Event | Enzalutamide |
|---|---|
| FatigueGeneral disorders | 43/60 |
| AnorexiaMetabolism and nutrition disorders | 17/60 |
| ConstipationGastrointestinal disorders | 17/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 16/60 |
| Back painMusculoskeletal and connective tissue disorders | 14/60 |
| Oedema peripheralGeneral disorders | 14/60 |
| NauseaGastrointestinal disorders | 11/60 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 10/60 |
| Hot FlushVascular disorders | 9/60 |
| Bone painMusculoskeletal and connective tissue disorders | 8/60 |
| Age, Continuous(years) | Enzalutamide |
|---|---|
| Mean | 67.9 ± 9.99 |
| Age, Customized(years) | Enzalutamide |
|---|---|
| < 55 | 6 |
| 55 to < 65 | 17 |
| 65 to < 75 | 18 |
| >= 75 | 19 |
| Sex: Female, Male(Participants) | Enzalutamide |
|---|---|
| Female | 0 |
| Male | 60 |
Ran from Feb 2010 to primary completion in Feb 2012, 24 months.
Results were first posted in Nov 2014, 2 years 8 months after primary completion.
Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 24 months is below that.
Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide